Advances in Nano Drugs for Cancer Chemotherapy

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

In spite of some medications, millions of people are dying every year due to cancer. Additionally, the survival patients suffer from various serious side effects due to the use of available anti-neoplastic medicines. The development of nanoparticle based drugs seems to be effective providing low side effects and targeted action on cancer cells. The present article describes the state-of-the-art of nano drugs in cancer chemotherapy. The nano drugs are target selective and specific towards tumors only resulting into better treatment. The important molecules used for preparation nano drugs are cisplatin, carboplatin, bleomycin, 5-fluorouracil, doxorubicin, dactinomycin, 6-mercaptopurine, paclitaxel, topotecan, vinblastin and etoposide etc. The most commonly used materials for nanoparticle carriers are dendrimers, polymers, liposomes, micelles, inorganic, organic nanoparticles etc. A survey was carried out on the drugs available in the market and given in tabular form. However, the commonly used nano drugs till date are liposome dendrimer and some other materials based on nanoparticles. Attempts have been made to explain the mechanism of action of nano drugs. The future perspectives have also been highlighted in the conclusion part.





More about this publication?
  • Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
    Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
    As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more